Fidelity International’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $166M | Sell |
265,490
-44,019
| -14% | -$30M | 0.12% | 178 |
|
|
2026
Q1 | $239M | Sell |
309,509
-219,681
| -42% | -$168M | 0.19% | 138 |
|
|
2025
Q4 | $408M | Buy |
529,190
+341,666
| +182% | +$232M | 0.31% | 81 |
|
|
2025
Q3 | $105M | Buy |
187,524
+21,438
| +13% | +$12.1M | 0.08% | 224 |
|
|
2025
Q2 | $87.2M | Buy |
166,086
+81,013
| +95% | +$45.2M | 0.07% | 243 |
|
|
2025
Q1 | $54M | Sell |
85,073
-20,968
| -20% | -$14.4M | 0.05% | 302 |
|
|
2024
Q4 | $75.5M | Buy |
106,041
+5,232
| +5% | +$4.39M | 0.07% | 247 |
|
|
2024
Q3 | $106M | Buy |
100,809
+6,310
| +7% | +$7.02M | 0.1% | 221 |
|
|
2024
Q2 | $99.3M | Buy |
94,499
+5,240
| +6% | +$5.08M | 0.1% | 216 |
|
|
2024
Q1 | $85.9M | Buy |
89,259
+9,613
| +12% | +$9.14M | 0.09% | 244 |
|
|
2023
Q4 | $70M | Buy |
79,646
+18,654
| +31% | +$15.4M | 0.07% | 275 |
|
|
2023
Q3 | $50.2M | Buy |
60,992
+22,157
| +57% | +$17.4M | 0.06% | 294 |
|
|
2023
Q2 | $27.9M | Buy |
38,835
+34,118
| +723% | +$26.3M | 0.03% | 372 |
|
|
2023
Q1 | $3.88M | Sell |
4,717
-588
| -11% | -$443K | ﹤0.01% | 602 |
|
|
2022
Q4 | $3.83M | Buy |
5,305
+5,303
| +265,150% | +$3.91M | ﹤0.01% | 610 |
|
|
2022
Q3 | $1K | Buy |
+2
| New | +$1.26K | ﹤0.01% | 830 |
|
|
2022
Q2 | – | Sell |
-400
| Closed | -$279K | – | 858 |
|
|
2022
Q1 | $279K | Sell |
400
-147,994
| -100% | -$93.6M | ﹤0.01% | 780 |
|
|
2021
Q4 | $93.7M | Sell |
148,394
-263,668
| -64% | -$162M | 0.1% | 216 |
|
|
2021
Q3 | $249M | Sell |
412,062
-57,124
| -12% | -$35.5M | 0.28% | 89 |
|
|
2021
Q2 | $262M | Buy |
469,186
+83,083
| +22% | +$42.1M | 0.28% | 85 |
|
|
2021
Q1 | $183M | Buy |
386,103
+124,556
| +48% | +$60.6M | 0.21% | 129 |
|
|
2020
Q4 | $126M | Sell |
261,547
-22,812
| -8% | -$12.3M | 0.16% | 160 |
|
|
2020
Q3 | $159M | Sell |
284,359
-278,104
| -49% | -$169M | 0.2% | 134 |
|
|
2020
Q2 | $351M | Buy |
562,463
+85,490
| +18% | +$48.5M | 0.47% | 51 |
|
|
2020
Q1 | $233M | Buy |
476,973
+476,952
| +2,271,200% | +$197M | 0.38% | 60 |
|
|
2019
Q4 | $8K | Buy |
21
+1
| +5% | +$336 | ﹤0.01% | 756 |
|
|
2019
Q3 | $6K | Hold |
20
| – | – | ﹤0.01% | 724 |
|
|
2019
Q2 | $6K | Hold |
20
| – | – | ﹤0.01% | 729 |
|
|
2019
Q1 | $8K | Buy |
+20
| New | +$8.24K | ﹤0.01% | 705 |
|
|
2018
Q1 | – | Sell |
-11,257
| Closed | -$4.23M | – | 531 |
|
|
2017
Q4 | $4.23M | Hold |
11,257
| – | – | 0.01% | 427 |
|
|
2017
Q3 | $5.03M | Sell |
11,257
-15,681
| -58% | -$7.46M | 0.01% | 398 |
|
|
2017
Q2 | $13.2M | Sell |
26,938
-6,120
| -19% | -$2.68M | 0.04% | 303 |
|
|
2017
Q1 | $12.8M | Sell |
33,058
-2,782
| -8% | -$1.03M | 0.04% | 318 |
|
|
2016
Q4 | $13.2M | Buy |
35,840
+1,689
| +5% | +$642K | 0.04% | 304 |
|
|
2016
Q3 | $13.7M | Hold |
34,151
| – | – | 0.04% | 302 |
|
|
2016
Q2 | $11.9M | Sell |
34,151
-3,041
| -8% | -$1.17M | 0.04% | 316 |
|
|
2016
Q1 | $13.4M | Buy |
37,192
+24,567
| +195% | +$10.1M | 0.04% | 306 |
|
|
2015
Q4 | $6.85M | Hold |
12,625
| – | – | 0.02% | 355 |
|
|
2015
Q3 | $5.87M | Buy |
+12,625
| New | +$6.78M | 0.02% | 370 |
|
Other funds holding REGN
Fidelity International's REGN Position: Q2 2026 in Review
Fidelity International reduced its Regeneron Pharmaceuticals (REGN) stake by 14% in Q2 2026, selling an estimated $30M and leaving 265,490 shares worth $166M. The position accounts for 0.12% of the portfolio, ranked #178.
Fidelity International first reported a position in REGN in Q3 2015 and has held it in 39 quarters since. The position peaked at $408M in Q4 2025. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Fidelity International held 265,490 shares of Regeneron Pharmaceuticals worth $166M as of Q2 2026.
- Fidelity International sold 44,019 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $30M.
- Regeneron Pharmaceuticals made up 0.12% of Fidelity International's portfolio in Q2 2026, its #178 holding.
- Fidelity International first reported a position in Regeneron Pharmaceuticals in Q3 2015 and has held it in 39 quarters since.
- Fidelity International's Regeneron Pharmaceuticals position peaked at $408M in Q4 2025.
- 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Fidelity International's 13F filing for Q2 2026, filed 13 Aug 2026.